| Mckinzie Marie Nuss, DNP | |
|
222 N 7th St, Bismarck, ND 58501-4436 | |
| (701) 323-5422 | |
| Not Available |
| Full Name | Mckinzie Marie Nuss |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 222 N 7th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700446192 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R39084 (North Dakota) | Secondary |
| 363L00000X | Nurse Practitioner | R39084 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Chi St Alexius Health Dickinson | Dickinson, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Bismarck | 9739098575 | 448 |
News Archive
In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 100 national research and training grants totaling more than $45.6 million in the first of two grant cycles for 2015.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate detoxification. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in this patient group.
› Verified 8 days ago
| Entity Name | Sanford Bismarck |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 100 national research and training grants totaling more than $45.6 million in the first of two grant cycles for 2015.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate detoxification. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in this patient group.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mckinzie Marie Nuss, DNP Po Box 5074, Sioux Falls, SD 57117-5074 Ph: (605) 328-6585 | Mckinzie Marie Nuss, DNP 222 N 7th St, Bismarck, ND 58501-4436 Ph: (701) 323-5422 |
News Archive
In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 100 national research and training grants totaling more than $45.6 million in the first of two grant cycles for 2015.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate detoxification. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in this patient group.
› Verified 8 days ago
Sarah Miller, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-5422 Fax: 701-323-8645 | |
Danette Pengilly, GNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th St, Bismarck, ND 58501 Phone: 701-530-7500 Fax: 701-530-7484 | |
Jana Rakowski, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1040 Tacoma Ave, Bismarck, ND 58504 Phone: 701-323-7452 Fax: 701-323-6982 | |
Mrs. Christina R Gisvold, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Lee Ann June Short, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-204-1709 | |
Rebecca L Ritter, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 E Rosser Ave, Bismarck, ND 58501 Phone: 701-530-6000 Fax: 701-530-6430 | |
Cheryle K Bitz, MSN, ARNP, GNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7300 Fax: 701-530-7319 |